PRO 542. CD4 IgG2.
D000328:Adult; D019380:Anti-HIV Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D016860:CD4 Immunoadhesins / Q000494:pharmacology* / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D002452:Cell Count; D002648:Child; D015507:Drugs, Investigational / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D015726:Giant Cells / Q000187:drug effects; D015699:HIV Envelope Protein gp120 / Q000187:drug effects / Q000378:metabolism; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy; D006207:Half-Life; D006801:Humans
D019380:Anti-HIV Agents; D016860:CD4 Immunoadhesins; C096753:CD4-IgG(2); D015507:Drugs, Investigational; D015699:HIV Envelope Protein gp120